Systems approach to tuberculosis vaccine development

Respirology

Volumn 18, Issue 3, 2013, Pages 412-420

  Wang, Charles C ^a   Zhu, Bingdong ^b   Fan, Xionglin ^c   Gicquel, Brigitte ^f,g   Zhang, Ying ^a,d,e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b LANZHOU UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d FUDAN UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

^f INSTITUTE PASTEUR OF SHANGHAI   (China)

^g INSTITUT PASTEUR   (France)

Author keywords

immunology; mycobacterial infection; Mycobacterium tuberculosis; systems biology; tuberculosis vaccine

Indexed keywords

ALPHA CRYSTALLIN; ANTIGEN; ANTIGEN 85A; ANTIGEN 85B; BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; HEAT SHOCK PROTEIN; RECOMBINANT VACCINE; RV0125 ANTIGEN; RV1196 ANTIGEN; RV2660C ANTIGEN; UNCLASSIFIED DRUG;

HOST; IMMUNOLOGY; LATENT PERIOD; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

DRUG DESIGN; HUMANS; IMMUNITY, CELLULAR; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84875639978     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12052     Document Type: Review

References (83)

1. Frieden TR, Sterling TR, Munsiff SS, et al. Tuberculosis. Lancet 2003; 362: 887-899.
2. World Health Organization. Global tuberculosis control 2011. 2011: 1-258. [Accessed 13 August 2012.] Available from URL: http://www.who.int/tb/ publications/global-report/2011/gtbr11-full.pdf
3. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. U.S.A. 2009; 106: 13980-13985.
4. Kaufmann SHE,. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010; 33: 567-577.
5. Aronson J,. Protective vaccination against tuberculosis with special reference to BCG vaccine. Am. Rev. Tuberc. 1948; 58: 55-81.
6. Comstock G, Livesay V, Woolpert S,. Evaluation of BCG vaccination among Puerto Rican children. Am. J. Public Health 1974; 64: 284-291.
7. Plotkin SA,. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008; 47: 401-409.
8. Zhang Y,. Immunopathogenesis of tuberculosis: implications for vaccine development. Respirology 2008; 13: S81-S87.
9. Lalvani A, Sridhar S,. BCG vaccination: 90 years on and still so much to learn. Thorax 2010; 65: 1036-1038.
10. Kagina BMN, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after Bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 2010; 182: 1073-1079.
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001; 69: 89-95.
12. Flynn JL,. Immunology of tuberculosis and implications in vaccine development. Tuberculosis 2004; 84: 93-101.
13. Dheda K, Schwander S, Zhu B, et al. The immunology of tuberculosis: from bench to bedside. Respirology 2010; 15: 433-450.
14. Nicholson S, Bonecini-Almeida MDG, Lapa e Silva JR, et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J. Exp. Med. 1996; 183: 2293-2302.
15. Armstrong J, D'Arcy Hart P,. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 1971; 134: 713-740.
16. Wolf AJ, Desvignes L, Linas B, et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 2008; 205: 105-115.
17. Day TA, Koch M, Nouailles G, et al. Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosis. Eur. J. Immunol. 2010; 40: 1663-1673.
18. Reece ST, Kaufmann S,. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? Curr. Opin. Microbiol. 2011; 15: 63-70.
19. Ottenhoff THM, Kaufmann SHE,. Vaccines against tuberculosis: where are we and where do we need to go?, Chitnis CE, ed. PLoS Pathog. 2012; 8: e1002607.
20. Levitz SM, Golenbock DT,. Beyond empiricism: informing vaccine development through innate immunity research. Cell 2012; 148: 1284-1292.
21. Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012; 148: 434-446.
22. Egen JG, Rothfuchs AG, Feng CG, et al. Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas. Immunity 2011; 34: 807-819.
23. Cooper AM,. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 2009; 27: 393-422.
24. Cruz A, Fraga AG, Fountain JJ, et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J. Exp. Med. 2010; 207: 1609-1616.
25. Joosten SA, van Meijgaarden KE, van Weeren PC, et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8+ T-cells with cytotoxic as well as regulatory activity. PLoS Pathog. 2010; 6: e1000782.
26. Joosten SA, Ottenhoff THM,. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum. Immunol. 2008; 69: 760-770.
27. Martineau AR, Newton SM, Wilkinson KA, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J. Clin. Invest. 2007; 117: 1988-1994.
28. Lowe DM, Redford PS, Wilkinson RJ, et al. Neutrophils in tuberculosis: friend or foe? Trends Immunol. 2012; 33: 14-25.
29. Gengenbacher M, Kaufmann SHE,. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol. Rev. 2012; 36: 514-532.
30. Keren I, Minami S, Rubin E, et al. Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. MBio. 2011; 2: e00100-00111.
31. Zhang Y, Yew WW, Barer MR,. Targeting persisters for tuberculosis control. Antimicrob. Agents Chemother. 2012; 56: 2223-2230.
32. Kaufmann SH, Hussey G, Lambert P-H,. New vaccines for tuberculosis. Lancet 2010; 375: 2110-2119.
33. Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 2011; 17: 189-194.
34. Hawkridge T, Mahomed H,. Prospects for a new, safer and more effective TB vaccine. Paediatr. Respir. Rev. 2011; 12: 46-51.
35. Parida SK, Kaufmann SH,. Novel tuberculosis vaccines on the horizon. Curr. Opin. Immunol. 2010; 22: 374-384.
36. WHO, Tuberculosis vaccine candidates-2011: Stop TB Partnership Working Group on new TB vaccines. 2012: 1-14. [Accessed 2 October 2012.] Available from URL: http://www.stoptb.org/wg/new-vaccines/assets/documents/ TB%20Vaccine%20Pipeline%202011-FINAL.pdf
37. Wang C, Fu R, Chen Z, et al. Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B. Clin. Dev. Immunol. 2012; 2012: 563838.
38. Sweeney KA, Dao DN, Goldberg MF, et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat. Med. 2011; 17: 1261-1268.
39. Kaufmann SHE,. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol. 2012; 33: 373-379.
40. Lin PL, Dietrich J, Tan E, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 2012; 122: 303-314.
41. Yuan W, Dong N, Zhang L, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice. Vaccine 2012; 30: 2490-2497.
42. Niu H, Hu L, Li Q, et al. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Vaccine 2011; 29: 9451-9458.
43. Shi C, Chen L, Chen Z, et al. Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine 2010; 28: 5237-5244.
44. Dey B, Jain R, Gupta UD, et al. A booster vaccine expressing a latency-Associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis. PLoS ONE 2011; 6: e23360.
45. Taylor JL, Wieczorek A, Keyser AR, et al. HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule. Immunol. Cell Biol. 2012; 00: 1-10.
46. Li Q, Yu H, Zhang Y, et al. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Scand. J. Immunol. 2011; 73: 568-576.
47. Brennan MJ, Clagett B, Fitzgerald H, et al. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 2012; 30: 2811-2823.
48. Temmerman S, Pethe K, Parra M, et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat. Med. 2004; 10: 935-941.
49. Guerrero GG, Debrie A-S, Locht C,. Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis. Vaccine 2010; 28: 4340-4347.
50. Mollenkopf H-J, Grode L, Mattow J, et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun. 2004; 72: 6471-6479.
51. Lu J, Wang C, Zhou Z, et al. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin. Dev. Immunol. 2011; 2011: 617892.
52. Wang C, Chen Z, Fu R, et al. A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice. Med. Microbiol. Immunol. 2011; 200: 165-175.
53. Maglione PJ, Chan J,. How B cells shape the immune response against Mycobacterium tuberculosis. Eur. J. Immunol. 2009; 39: 676-686.
54. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 2011; 12: 15-22.
55. Comas I, Chakravartti J, Small PM, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 2010; 42: 498-503.
56. Barreiro L, Tailleux L, Pai A, et al. Deciphering the genetic architecture of variation in the immune response to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. U.S.A. 2012; 109: 1-6.
57. Jeyanathan M, Heriazon A, Xing Z,. Airway luminal T cells: a newcomer on the stage of TB vaccination strategies. Trends Immunol. 2010; 31: 247-252.
58. Moreno-Mendieta SA, Rocha-Zavaleta L, Rodriguez-Sanoja R,. Adjuvants in tuberculosis vaccine development. FEMS Immunol. Med. Microbiol. 2010; 58: 75-84.
59. Young D, Stark J, Kirschner D,. Systems biology of persistent infection: tuberculosis as a case study. Nat. Rev. Microbiol. 2008; 6: 520-528.
60. Singh VK, Ghosh I,. Kinetic modeling of tricarboxylic acid cycle and glyoxylate bypass in Mycobacterium tuberculosis, and its application to assessment of drug targets. Theor. Biol. Med. Model. 2006; 3: 27-38.
61. Boshoff HIM, Lun DS,. Systems biology approaches to understanding mycobacterial survival mechanisms. Drug Discov. Today Dis. Mech. 2010; 7: e75-e82.
62. Raman K, Bhat AG, Chandra N,. A systems perspective of host-pathogen interactions: predicting disease outcome in tuberculosis. Mol. BioSyst. 2010; 6: 516-530.
63. Beste DJV, Hooper T, Stewart G, et al. GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism. Genome Biol. 2007; 8: R89.
64. Jamshidi N, Palsson BØ,. Investigating the metabolic capabilities of Mycobacterium tuberculosis H37Rv using the in silico strain iNJ661 and proposing alternative drug targets. BMC Syst. Biol. 2007; 1: 26-46.
65. Colijn C, Brandes A, Zucker J, et al. Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production. PLoS Comput. Biol. 2009; 5: e1000489.
66. Day J, Friedman A, Schlesinger LS,. Modeling the immune rheostat of macrophages in the lung in response to infection. Proc. Natl Acad. Sci. U.S.A. 2009; 106: 11246-11251.
67. Bru A, Cardona P-J,. Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice., Pai M, ed. PLoS ONE 2010; 5: e12985.
68. Jung YJ,. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 2005; 201: 1915-1924.
69. Fallahi-Sichani M, Schaller MA, Kirschner DE, et al. Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma. PLoS Comput. Biol. 2010; 6: e1000778.
70. Marino S, Linderman JJ, Kirschner DE,. A multifaceted approach to modeling the immune response in tuberculosis. Wiley Interdiscip. Rev. Syst. Biol. Med. 2011; 3: 479-489.
71. Oberg AL, Kennedy RB, Li P, et al. Systems biology approaches to new vaccine development. Curr. Opin. Immunol. 2011; 23: 436-443.
72. Day J, Schlesinger LS, Friedman A,. Tuberculosis research: going forward with a powerful Translational Systems Biology approach. Tuberculosis 2010; 90: 7-8.
73. Kennedy RB, Poland GA,. The top five 'game changers' in vaccinology: toward rational and directed vaccine development. OMICS 2011; 15: 533-537.
74. Ovsyannikova IG, Poland GA,. Vaccinomics: current findings, challenges and novel approaches for vaccine development. AAPS J. 2011; 13: 438-444.
75. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2008; 10: 116-125.
76. Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 2008; 205: 3119-3131.
77. Locht C, Hougardy J-M, Rouanet C, et al. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis 2006; 86: 303-309.
78. Berry MPR, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-977.
79. Aranday Cortes E, Kaveh D, Nunez-Garcia J, et al. Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice. PLoS ONE 2010; 5: e11319.
80. Zárate-Bladés CR, Bonato VLD, da Silveira ELV, et al. Comprehensive gene expression profiling in lungs of mice infected with Mycobacterium tuberculosis following DNAhsp65 immunotherapy. J. Gene Med. 2009; 11: 66-78.
81. Sundaramurthi JC, Brindha S, Shobitha SR, et al. In silico identification of potential antigenic proteins and promiscuous CTL epitopes in Mycobacterium tuberculosis. Infect. Genet. Evol. 2012; 12: 1312-1318.
82. Young D, Verreck FAW,. Creativity in tuberculosis research and discovery. Tuberculosis (Edinb) 2012; 92: S14-16.
83. Sizemore CF, Fauci AS,. Transforming biomedical research to develop effective TB vaccines: the next ten years. Tuberculosis (Edinb) 2012; 92: S2-3.